The University of California, San Francisco (UCSF) is actively recruiting participants for three clinical trials exploring the effects of psilocybin on various mental health conditions, including Alzheimer’s disease and depressions/anxiety associated with advanced cancer.
Psilocybin mushrooms.
The first study, titled “Psilocybin for Depression and Anxiety in Patients With Advanced Cancer“, will investigate the potential of psilocybin to alleviate depression and anxiety in patients with advanced cancer. Participants will receive psilocybin or a placebo alongside psychotherapy sessions to assess the compound’s efficacy.
Another study, “Exploring Psilocybin as a Treatment for Depression in Adults With Mild Cognitive Impairment“, focuses on adults diagnosed with mild cognitive impairment (MCI). The trial aims to determine if psilocybin can reduce symptoms of depression in this population, with results expected to offer insights into potential new treatments for those with MCI.
The third trial, “Psilocybin and Depression Treatment in Early Onset Alzheimer’s Disease“, targets individuals with early onset Alzheimer’s disease. Researchers will examine whether psilocybin can help manage depression symptoms commonly associated with this condition.
These studies reflect UCSF’s commitment to exploring novel therapeutic options for complex mental health issues. For more information or to enroll in any of these trials, interested individuals are encouraged to visit the UCSF Clinical Trials website by clicking here.
UCSF is also conducting four additional psilocybin clinical trials that are “not yet accepting patients”.
More articles from The Marijuana Herald:
